Auspex Pharmaceuticals Inc. (ASPX) 65.76 $ASPX
InsiderInsights.com Daily Round Up 2/11/15: GRUB, FSC, RENT, SXC
InsiderInsights - at Seeking Alpha - Thu Feb 12, 11:02AM CST
GRA: 101.61 (+1.69), GRUB: 39.93 (+1.71), SXC: 17.32 (+0.58), RENT: 58.90 (+0.39), ASPX: 65.76 (+2.76), BH: 416.41 (-1.55), NOW: 77.55 (+1.60), FSC: 7.23 (+0.12), NWL: 39.57 (+0.32), AST: 3.85 (+0.13), AVNU: 11.84 (+0.22), WDR: 49.94 (+0.15), DATA: 99.90 (+1.40), CRM: 62.85 (+1.59)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
InsiderInsights.com Daily Round Up 2/6/15: X, IBTX, SHAK, TWTR
InsiderInsights - at Seeking Alpha - Sat Feb 07, 11:56PM CST
RH: 86.77 (-1.55), SHAK: 40.69 (+0.04), CRR: 40.35 (+2.73), STX: 61.83 (+0.67), BAH: 30.16 (+0.18), EPRS: 7.67 (+0.67), ASPX: 65.76 (+2.76), MLNK: 3.78 (+0.04), IBTX: 38.53 (-0.08), WIW: 11.29 (unch), ONCE: 46.25 (+0.07), CUDA: 35.68 (-1.14), CDNA: 6.30 (-0.14), NMIH: 8.41 (-0.09), TWTR: 48.50 (+0.55), MSFT: 43.87 (+0.78), X: 26.36 (+1.12), CTSH: 60.23 (-0.05)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.06 (+0.92), GPRO: 45.27 (-0.02), CLDN: 16.45 (-0.05), ZEN: 25.38 (+1.02), ASPX: 65.76 (+2.76), TNET: 36.49 (+0.76), NVRO: 43.70 (+0.57), OCUL: 31.25 (-0.01), RDUS: 50.37 (+0.63), ALDR: 26.06 (+0.18), IRMD: 14.61 (-0.35), KITE: 62.59 (+0.82), TUBE: 15.69 (+0.93), VBLT: 14.11 (+0.24)
Auspex Pharma completes enrollment in tardive dyskinesia trial
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 6:23AM CST
ASPX: 65.76 (+2.76)
Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
GlobeNewswire - Tue Feb 03, 5:30AM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that it has completed target enrollment in its pivotal clinical trial of SD-809 for the potential treatment of tardive dyskinesia (TD), called ARM-TD (Aim to Reduce Movement in TD). The company expects to announce topline data from this study in mid-2015.
ASPX: 65.76 (+2.76)
Auspex to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 02, 3:00PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that Pratik Shah, Ph.D., president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 2:40 p.m. EDT at the Waldorf Astoria in New York City.
ASPX: 65.76 (+2.76)
Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots
GuruFundPicks - at Seeking Alpha - Thu Jan 29, 7:04PM CST
BLUE: 90.70 (+0.93), ABMD: 60.39 (+0.46), AUXL: 36.47 (-0.06), ASPX: 65.76 (+2.76), AAVL: 36.29 (+0.01)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 4.60 (+0.44), RNST: 27.87 (+0.28), ASPX: 65.76 (+2.76), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), SNI: 73.00 (+0.39), ADBE: 76.51 (+1.92), VSTM: 7.93 (-0.44), ALDR: 26.06 (+0.18), ALNY: 95.54 (+1.67), SSP: 20.91 (+0.47), SGNT: 27.75 (-0.41), MA: 87.14 (-0.38), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59), SCHW: 29.13 (-0.83)
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Jan 28, 3:09PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $56.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares of common stock. Auspex sold 3,600,000 shares of common stock and certain existing stockholders of Auspex sold 1,000,000 shares of common stock. The gross proceeds to Auspex from this offering were approximately $203.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex. Auspex did not receive any proceeds from the sale of the shares by the selling stockholders.
JPM: 59.67 (+0.10), ASPX: 65.76 (+2.76)
Podcast: Why the biotech boom is still in the 1st inning
ESTMZ - Wed Jan 28, 12:55PM CST
In the latest episode of our weekly podcast, This Week on Estimize , our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights . Joe tells us why he believes the biotech boom still has plenty...
BDSI: 14.92 (+0.93), GILD: 101.90 (+1.10), RTRX: 13.92 (+0.44), ASPX: 65.76 (+2.76)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Auspex prices follow on public offering at USD56.50 per share
M2 - Mon Jan 26, 4:26AM CST
Biopharmaceutical company Auspex Pharmaceuticals (NasdaqGM:ASPX) declared on Friday that it has priced its public offering of 4,000,000 common stock at USD56.50 per share.
ASPX: 65.76 (+2.76)
Auspex Announces Pricing of Follow on Offering
GlobeNewswire - Fri Jan 23, 7:32AM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $56.50 per share. Auspex is offering 3,000,000 shares of common stock and certain existing stockholders of Auspex are offering 1,000,000 shares of common stock. The gross proceeds to Auspex from this offering are expected to be approximately $169.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex. In addition, the underwriters of the offering have been granted a 30-day option to purchase from Auspex up to an additional 600,000 shares of common stock, on the same terms and conditions. Auspex will not receive any proceeds from the sale of the shares by the selling stockholders. J.P. Morgan Securities LLC is sole book-running manager for the offering. In addition, Stifel and BMO Capital Markets Corp. are acting as co-lead managers, and Robert W. Baird & Co. Incorporated and William Blair and Company, L.L.C., are acting as co-managers. Maxim Group LLC is acting as an advisor to Auspex.
JPM: 59.67 (+0.10), ASPX: 65.76 (+2.76)
Auspex prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 7:27AM CST
ASPX: 65.76 (+2.76)
Auspex intends to launch public offering of 4m common shares
M2 - Thu Jan 22, 5:24AM CST
Biopharmaceutical company Auspex Pharmaceuticals (NasdaqGM:ASPX) reported on Wednesday the start of its public offering of 4,000,000 shares of its common stock.
ASPX: 65.76 (+2.76)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 4:35PM CST
NRP: 7.86 (-0.45), SLM: 9.26 (-0.01), TAC: 8.76 (+0.05), MDR: 2.77 (+0.12), XLNX: 41.51 (+0.51), NERV: 4.68 (+0.09), FFIV: 116.64 (+1.37), OKS: 45.47 (+0.07), ASPX: 65.76 (+2.76), NE: 18.54 (+0.30)
Auspex Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 3:39PM CST
ASPX: 65.76 (+2.76)
Auspex Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 21, 3:32PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The offering is expected to consist of 3,000,000 shares of common stock to be offered by Auspex and 1,000,000 shares of common stock to be offered by selling stockholders. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase from Auspex up to an additional 600,000 shares of common stock, on the same terms and conditions.
ASPX: 65.76 (+2.76)
InsiderInsights.com Daily Round Up 2/11/15: GRUB, FSC, RENT, SXC
InsiderInsights - at Seeking Alpha - Thu Feb 12, 11:02AM CST
GRA: 101.61 (+1.69), GRUB: 39.93 (+1.71), SXC: 17.32 (+0.58), RENT: 58.90 (+0.39), ASPX: 65.76 (+2.76), BH: 416.41 (-1.55), NOW: 77.55 (+1.60), FSC: 7.23 (+0.12), NWL: 39.57 (+0.32), AST: 3.85 (+0.13), AVNU: 11.84 (+0.22), WDR: 49.94 (+0.15), DATA: 99.90 (+1.40), CRM: 62.85 (+1.59)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
InsiderInsights.com Daily Round Up 2/6/15: X, IBTX, SHAK, TWTR
InsiderInsights - at Seeking Alpha - Sat Feb 07, 11:56PM CST
RH: 86.77 (-1.55), SHAK: 40.69 (+0.04), CRR: 40.35 (+2.73), STX: 61.83 (+0.67), BAH: 30.16 (+0.18), EPRS: 7.67 (+0.67), ASPX: 65.76 (+2.76), MLNK: 3.78 (+0.04), IBTX: 38.53 (-0.08), WIW: 11.29 (unch), ONCE: 46.25 (+0.07), CUDA: 35.68 (-1.14), CDNA: 6.30 (-0.14), NMIH: 8.41 (-0.09), TWTR: 48.50 (+0.55), MSFT: 43.87 (+0.78), X: 26.36 (+1.12), CTSH: 60.23 (-0.05)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 39.06 (+0.92), GPRO: 45.27 (-0.02), CLDN: 16.45 (-0.05), ZEN: 25.38 (+1.02), ASPX: 65.76 (+2.76), TNET: 36.49 (+0.76), NVRO: 43.70 (+0.57), OCUL: 31.25 (-0.01), RDUS: 50.37 (+0.63), ALDR: 26.06 (+0.18), IRMD: 14.61 (-0.35), KITE: 62.59 (+0.82), TUBE: 15.69 (+0.93), VBLT: 14.11 (+0.24)
Auspex Pharma completes enrollment in tardive dyskinesia trial
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 6:23AM CST
ASPX: 65.76 (+2.76)
Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
GlobeNewswire - Tue Feb 03, 5:30AM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that it has completed target enrollment in its pivotal clinical trial of SD-809 for the potential treatment of tardive dyskinesia (TD), called ARM-TD (Aim to Reduce Movement in TD). The company expects to announce topline data from this study in mid-2015.
ASPX: 65.76 (+2.76)
Auspex to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 02, 3:00PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that Pratik Shah, Ph.D., president and chief executive officer, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 2:40 p.m. EDT at the Waldorf Astoria in New York City.
ASPX: 65.76 (+2.76)
Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots
GuruFundPicks - at Seeking Alpha - Thu Jan 29, 7:04PM CST
BLUE: 90.70 (+0.93), ABMD: 60.39 (+0.46), AUXL: 36.47 (-0.06), ASPX: 65.76 (+2.76), AAVL: 36.29 (+0.01)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 4.60 (+0.44), RNST: 27.87 (+0.28), ASPX: 65.76 (+2.76), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), SNI: 73.00 (+0.39), ADBE: 76.51 (+1.92), VSTM: 7.93 (-0.44), ALDR: 26.06 (+0.18), ALNY: 95.54 (+1.67), SSP: 20.91 (+0.47), SGNT: 27.75 (-0.41), MA: 87.14 (-0.38), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59), SCHW: 29.13 (-0.83)
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Wed Jan 28, 3:09PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $56.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares of common stock. Auspex sold 3,600,000 shares of common stock and certain existing stockholders of Auspex sold 1,000,000 shares of common stock. The gross proceeds to Auspex from this offering were approximately $203.4 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex. Auspex did not receive any proceeds from the sale of the shares by the selling stockholders.
JPM: 59.67 (+0.10), ASPX: 65.76 (+2.76)
Podcast: Why the biotech boom is still in the 1st inning
ESTMZ - Wed Jan 28, 12:55PM CST
In the latest episode of our weekly podcast, This Week on Estimize , our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights . Joe tells us why he believes the biotech boom still has plenty...
BDSI: 14.92 (+0.93), GILD: 101.90 (+1.10), RTRX: 13.92 (+0.44), ASPX: 65.76 (+2.76)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Auspex prices follow on public offering at USD56.50 per share
M2 - Mon Jan 26, 4:26AM CST
Biopharmaceutical company Auspex Pharmaceuticals (NasdaqGM:ASPX) declared on Friday that it has priced its public offering of 4,000,000 common stock at USD56.50 per share.
ASPX: 65.76 (+2.76)
Auspex Announces Pricing of Follow on Offering
GlobeNewswire - Fri Jan 23, 7:32AM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $56.50 per share. Auspex is offering 3,000,000 shares of common stock and certain existing stockholders of Auspex are offering 1,000,000 shares of common stock. The gross proceeds to Auspex from this offering are expected to be approximately $169.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Auspex. In addition, the underwriters of the offering have been granted a 30-day option to purchase from Auspex up to an additional 600,000 shares of common stock, on the same terms and conditions. Auspex will not receive any proceeds from the sale of the shares by the selling stockholders. J.P. Morgan Securities LLC is sole book-running manager for the offering. In addition, Stifel and BMO Capital Markets Corp. are acting as co-lead managers, and Robert W. Baird & Co. Incorporated and William Blair and Company, L.L.C., are acting as co-managers. Maxim Group LLC is acting as an advisor to Auspex.
JPM: 59.67 (+0.10), ASPX: 65.76 (+2.76)
Auspex prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 7:27AM CST
ASPX: 65.76 (+2.76)
Auspex intends to launch public offering of 4m common shares
M2 - Thu Jan 22, 5:24AM CST
Biopharmaceutical company Auspex Pharmaceuticals (NasdaqGM:ASPX) reported on Wednesday the start of its public offering of 4,000,000 shares of its common stock.
ASPX: 65.76 (+2.76)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 4:35PM CST
NRP: 7.86 (-0.45), SLM: 9.26 (-0.01), TAC: 8.76 (+0.05), MDR: 2.77 (+0.12), XLNX: 41.51 (+0.51), NERV: 4.68 (+0.09), FFIV: 116.64 (+1.37), OKS: 45.47 (+0.07), ASPX: 65.76 (+2.76), NE: 18.54 (+0.30)
Auspex Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 3:39PM CST
ASPX: 65.76 (+2.76)
Auspex Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 21, 3:32PM CST
Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The offering is expected to consist of 3,000,000 shares of common stock to be offered by Auspex and 1,000,000 shares of common stock to be offered by selling stockholders. In addition, the company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase from Auspex up to an additional 600,000 shares of common stock, on the same terms and conditions.
ASPX: 65.76 (+2.76)
